InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
NewTimeSpace News: On 15 July 2026,InnoCare Pharma Limited(09969.HK) issued an announcement that Soficitinib (ICP-332), the Company’s self-developed new-generation oral TYK2 inhibitor, achieved successful primary endpoint results in the Phase III registrational clinical trial for moderate-to-severe atopic dermatitis.
Per the announcement, this Phase III study is a randomized, double-blind, placebo-controlled, multi-center registrational clinical trial. The results demonstrated statistically significant and clinically meaningful improvements for the primary endpoint, alongside the achievement of multiple secondary endpoints with consistent therapeutic efficacy observed.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- INNOCARE (09969.HK): Phase III Trial of Fadeucravacitinib (ICP-488) for Moderate to Severe Plaque Psoriasis Meets Primary Endpoint
- INNOCARE (09969.HK): TYK2 Inhibitor Soficitinib (ICP-332) Meets Primary Endpoint in Phase II for Non-Segmental Vitiligo, 24-Week F-VASI Reduced by Around 39%-41% vs Baseline
- INNOCARE(09969.HK): NDA of Orelabrutinib for ITP Accepted by NMPA
